Cagrilintide and Amylin Pharmacology in Metabolic Research

Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic β-cells in a roughly 1:100 molar ratio relative to insulin. Endogenous amylin is a regulator of post-prandial glucose excursion through a mechanism distinct from insulin: slowed gastric emptying, suppression of post-prandial glucagon, and engagement of central satiety circuits. Native amylin is impractical as a therapeutic because of its propensity to form amyloid fibrils — the protein is one of the canonical amyloidogenic peptides in the broader literature.

Pramlintide, an early non-aggregating amylin analog, has been clinically available since 2005 for adjunct use with insulin in diabetes. Cagrilintide represents the modern long-acting iteration of the same pharmacological concept — fatty-acid acylated for once-weekly dosing and engineered for non-aggregation — and is the principal compound in this brief.

The amylin receptors are heterodimeric assemblies of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs 1, 2, or 3), producing three distinct amylin receptors: AMY1 (CTR + RAMP1), AMY2 (CTR + RAMP2), and AMY3 (CTR + RAMP3). The receptor distribution in the central nervous system includes the area postrema and nucleus of the solitary tract, where amylin signaling engages central satiety pathways.

A pharmacologically important feature is that amylin agonists also bind the calcitonin receptor itself, producing some calcitonin-like activity at higher concentrations. The receptor selectivity of cagrilintide across this family has been characterized in the published pharmacology, with substantial activity at all three amylin receptors and the calcitonin receptor.

Cagrilintide is a 37-amino-acid analog of amylin with substitutions at positions 14, 21, and 24 that prevent fibrillation, and a fatty diacid linker at Lys26 that mediates reversible albumin binding for once-weekly pharmacokinetics. The compound is engineered specifically to combine the pharmacological activity of amylin with the long half-life profile required for modern once-weekly dosing.

The half-life is approximately 7–8 days in humans, with steady-state achieved over approximately 4–5 weeks of weekly dosing. The pharmacokinetic profile is comparable to semaglutide, which is relevant to the combination work discussed below.

Cagrilintide activation of central amylin receptors engages satiety pathways through the area postrema and nucleus of the solitary tract. The mechanism is distinct from GLP-1 signaling, which engages a different set of brainstem and hypothalamic populations. The receptor pathways converge on shared downstream effects (appetite suppression, reduced food intake) but operate through non-overlapping signaling.

This mechanistic distinction is the basis for combination pharmacology with GLP-1 agonists. The CagriSema combination program (cagrilintide + semaglutide) has been the principal context in which the compound has been evaluated clinically.

The CagriSema combination — cagrilintide and semaglutide co-administered, each at 2.4 mg once weekly — has been studied in Phase 1, 2, and 3 trials in metabolic-disease indications. The published Phase 1b data showed weight reductions exceeding what would be expected from either compound alone, supporting the additive-mechanism hypothesis.

Phase 2 data extended the signal across longer dosing durations and Phase 3 work (REDEFINE program) has been the principal evaluation against semaglutide alone. The published REDEFINE-1 trial in patients with overweight or obesity showed mean weight reduction with CagriSema versus semaglutide alone, though the incremental benefit was smaller than initial enthusiasm in the Phase 1 work suggested.

For practitioners familiar with the older pramlintide pharmacology, cagrilintide is the modern long-acting successor with substantially different clinical use case. Pramlintide is a short-acting compound dosed before meals as an adjunct to insulin in diabetes — a niche use because of injection burden and limited weight effect. Cagrilintide is a once-weekly compound studied primarily in combination with GLP-1 agonists for weight reduction, with a substantially different clinical profile.

Both compounds engage the same receptor pharmacology, but the practical applications are different enough that they should not be discussed as interchangeable.

The principal open question for cagrilintide is the magnitude of incremental benefit over selective GLP-1 agonism in combination protocols. The mechanism-level rationale for amylin + GLP-1 combination is well-supported, but the clinical-trial readouts have shown a smaller-than-expected incremental effect that warrants further characterization across patient populations and dosing regimens.

Secondary questions include the contribution of calcitonin-receptor activity to the overall profile, the durability of weight effects over multi-year dosing, and the relative position of amylin agonism in a pharmacological landscape now dominated by triple-incretin agonists like retatrutide.